figopitant
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 1999 (NCT02199899)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Neurokinin 1 receptorANTAGONIST
TACR1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CN(CCc1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(=O)[C@H](c1ccccc1)N1CCN(CC2CC2)CC1- Mol. weight
- 527.55 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2104927 ↗
Also known as
- biif-1149
- biif-1149
- biif 1149 bs
- biif 1149 bs
- biif-1149-bs
- biif-1149-bs
- biif 1149 cl
- biif-1149-cl
- biif-1149-cl
- figopitant
- figopitant
- figopitant
- figopitant
- n-(2-(3,5-bis(trifluoromethyl)phenyl)ethyl)-4-(cyclopropylmethyl)-n-methyl-alpha-phenyl-1-piperazineacetamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02203487 | Phase 1 | Nov 1, 1999 | Boehringer Ingelheim |
| NCT02209714 | Phase 1 | Nov 1, 1999 | Boehringer Ingelheim |
| NCT02199899 | Phase 1 | Mar 1, 1999 | Boehringer Ingelheim |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 3 | 3 | 1 | 1999 |
1 organizations
Page 1 / 1